Paradigm Biopharmaceuticals (ASX:PAR) has activated its first Australian clinical site as part of a Phase Three trial to assess injectable pentosan polysulfate sodium for the treatment of pain connected to knee osteoarthritis.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
The site will be located at Sportsmed Biologic in Melbourne, and directed by specialist sports physician Dr Phillip Bloom, who has more than two decades of clinical experience in osteoarthritis management.
This will be the first of 11 Australian sites earmarked for participation in the PARA_OA_012 study. Paradigm has also received informed consent from its first Australian patient, who will take part in the trial.
Alongside the Oz component, there will also be 48 sites in the States that are currently in advanced preparations for activation under the centralised ethics approval.
Managing director Paul Rennie said these were significant milestones for the Paradigm.
“The activation of our first site in Australia and the consenting of our first patients in Australia, with the US soon to follow, mark a significant operational achievement for the company,” Mr Rennie said.
More market news
Forget U.S. tariff talk: Aussies just got a worrying signal from the ABS
Meet GeoGeorge: The HotCopper poster so accurate he got hired as an analyst
He continued: “I am particularly pleased to see the high level of engagement from leading clinical investigators and trial sites.
“I am also pleased that the company is progressing in line with our intended schedule.”
PAR has been trading at 30.5 cents.
Join the discussion: See what HotCopper users are saying about Paradigm Biopharmaceuticals and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please clickhere.